Product InformationRegistration Status: Active
FRAXIPARINE INJECTION 2850 IU AXA/0.3ML is approved to be sold in Singapore with effective from 1988-06-25. It is marketed by DCH AURIGA SINGAPORE, with the registration number of SIN02147P.
This product contains Nadroparin 950 iu AXA/0.1ml in the form of INJECTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by ASPEN NOTRE DAME DE BONDEVILLE in FRANCE.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction
Mechanism of Action
The mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.
- Absorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.
- Nadroparin is metabolized in the liver.
The clearance of nadroparin is 21.4 +/- 7.0mL/min
Osteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.
Nadroparin | Nadroparin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.